-
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) [EA6192]
The purpose of the study is to evaluate and determine how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients ... -
A Phase 2 Randomized Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer
Magrolimab is a novel immune checkpoint inhibitor (targeting macrophages in the tumor to support killing of tumor). The purpose of the study is to determine ... -
Single-arm open label phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator s choice (IV/SC/Oral) for patients with intermediate high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (US multi-center) (STIMULUS MDS-US)
The purpose of the study is to describe and evaluate safety and efficacy of MBG453 (sabatolimab) in combination with FDA approved Hypomethylating agents (HMA). We ... -
The BAMM2 (BRAF Autophagy MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAFV600E/K Melanoma with elevated LDH
Hydroxychloroquine inhibits a process called autophagy which helps tumors survive. The purpose of the study is to see how well different treatments work when hydroxychloroquine ... -
A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor
The purpose of the study is designed to evaluate the efficacy and safety of BA3011 alone and in combination with nivolumab in patients with AXL-expressing ... -
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer
The purpose of the study is to determine the safety and efficacy of the combination of Radium-223 dichloride and paclitaxel. We want to know if ... -
Randomized Phase 2 Study of Erdafitinib vs Investigator Choice of Chemo in Subjects Who Received BCG and Recurred With HR NMIBC (42756493BLC2003)
The purpose of the study is to determine the safety and efficacy of erdafitinib in subjects with Non-Muscle-Invasive Bladder Cancer (NMIBC) and fibroblast growth factor ... -
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)
The purpose of the study is to determine the efficacy and safety of Pembrolizumab plus investigational Agents in combination with etoposide and Cisplatin or Carboplatin ... -
A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
The purpose of the study is to evaluate the anti-tumor activity of pembrolizumab with fulvestrant for subjects with metastatic, hormone receptor positive, HER2 negative breast ... -
A Phase II Study to Evaluate the Efficacy and Safety of GT90001 in Combination with Nivolumab as a Second-line Treatment in Subjects with Advanced Hepatocellular Carcinoma
The purpose of the study is to examine and assess the antitumor activities of Nivolumab in combination with GT90001 or Nivolumab alone in subjects with ...